Sepsis News and Research

Latest Sepsis News and Research

Study demonstrates clinical accuracy of Masimo's noninvasive, continuous hemoglobin monitoring technology

Masimo announced today that a new clinical study demonstrating the clinical accuracy of its noninvasive and continuous hemoglobin (SpHb®) monitoring technology breakthrough was presented last week at the Society for Technology in Anesthesia (STA) Annual Meeting.

19 Jan 2011

Cataloguing microbes in gut could lead to cause of necrotizing enterocolitis

Scientists have for the first time sequenced and reconstructed the genomes of most of the microbes in the gut of a premature newborn and documented how the microbe populations changed over time.

14 Jan 2011

Bill and Melinda Gates Foundation grants $1.5million to Liverpool University for bacterial study

A University of Liverpool-led consortium has received $1.5million from the Bill & Melinda Gates Foundation to study a bacterium that causes serious disease and epidemics in sub-Saharan Africa.

14 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Columbia research team identifies bacteria may play a key role in atherosclerosis

Dr. Emil Kozarov and a team of researchers at the Columbia University College of Dental Medicine have identified specific bacteria that may have a key role in vascular pathogenesis, specifically atherosclerosis, or what is commonly referred to as "hardening of the arteries" - the number one cause of death in the United States.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

Blocking activation of delta-PKC enzyme could protect lungs from neutrophil-mediated damage

All of us may be able to breathe a little easier now that scientists from Pennsylvania have found a new therapeutic target for controlling dangerous inflammation in the lungs. A new research report in the January 2011 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that blocking the activation of an enzyme called delta-protein kinase C (delta-PKC) could protect the lungs from neutrophil-mediated damage, which can result in out of control inflammation.

5 Jan 2011

Jury returns $7M verdict for failure to diagnose and treat cardiac tamponade in bypass surgery patient

A New York State Supreme Court Queens County jury returned a $7,000,000.00 verdict against Patrick Monteleone M.D. and Newell Robinson, M.D. where they failed to diagnose and treat cardiac tamponade (bleeding into the chest) in their patient who underwent cardiac bypass surgery on November 17, 2004.

23 Dec 2010

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Pfizer Inc today announced that it has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.

23 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

Researchers identify class of drugs that can promote RBC formation in anemic patients

By determining how corticosteroids act to promote red blood cell progenitor formation, Whitehead Institute researchers have identified a class of drugs that may be beneficial in anemias, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.

22 Dec 2010

New nanoparticle-based diagnostic platform provides rapid detection of sepsis

Blood poisoning can be fatal. If you suffer from sepsis, you used to have to wait as much as 48 hours for laboratory findings. A new diagnostic platform as big as a credit card will now supply the analysis after as little as an hour. This system is based on nanoparticles that are automatically guided by magnetic forces.

22 Dec 2010

Majority of nurses are unaware of simple diagnostic test for sepsis

bioMerieux, a world leader in the field of in vitro diagnostics, announced the results of a survey demonstrating that most critical care nurses are unaware of a simple diagnostic test that may dramatically improve outcomes for sepsis patients.

22 Dec 2010

Study finds occurrence of infection following surgical procedures

Delaying elective surgical procedures after a patient has been admitted to the hospital significantly increases the risk of infectious complications and raises hospital costs, according to the results of a new study in the December issue of the Journal of the American College of Surgeons.

16 Dec 2010

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

Independent investigators reported today that patients with paroxysmal nocturnal hemoglobinuria who were treated long-term with Soliris (eculizumab) achieved survival comparable to that of an age- and gender-matched normal population. Findings from this investigator-led analysis were reported in an oral presentation today at the 52nd American Society of Hematology Annual Meeting and Exposition in Orlando.

7 Dec 2010

$Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL$

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics, Inc. today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.

6 Dec 2010

$Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010$

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Sepsis News and Research

Latest Sepsis News and Research

Study demonstrates clinical accuracy of Masimo's noninvasive, continuous hemoglobin monitoring technology

Cataloguing microbes in gut could lead to cause of necrotizing enterocolitis

Bill and Melinda Gates Foundation grants $1.5million to Liverpool University for bacterial study

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Columbia research team identifies bacteria may play a key role in atherosclerosis

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

GLUMETZA tablets are now available to wholesalers and physicians

Blocking activation of delta-PKC enzyme could protect lungs from neutrophil-mediated damage

Jury returns $7M verdict for failure to diagnose and treat cardiac tamponade in bypass surgery patient

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Researchers identify class of drugs that can promote RBC formation in anemic patients

New nanoparticle-based diagnostic platform provides rapid detection of sepsis

Majority of nurses are unaware of simple diagnostic test for sepsis

Study finds occurrence of infection following surgical procedures

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Sepsis News and Research

Latest Sepsis News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in